Strategy (MSTR) Stock Dips Despite Massive $2.54B Bitcoin Acquisition
Strategy (MSTR) stock dropped 2.5% pre-market after purchasing 34,164 bitcoin for $2.54B, its third-largest buy, funded through st...
Northrop Grumman (NOC) Q1 Earnings Preview: Margin Expansion Takes Center Stage...
Northrop Grumman (NOC) reports Q1 earnings Tuesday. Analysts expect $6.05 EPS on $9.76B revenue. Margin recovery and guidance rema...
Marvell Technology (MRVL) Stock: Custom AI Chips and Google Partnership Drive Gr...
Marvell (MRVL) stock analysis: Record $8.19B revenue, 42% YoY growth, and potential Google AI chip partnership position MRVL as ke...
OpenAI Prepares to Challenge Google With Advanced AI Image Generator
OpenAI plans to launch an advanced AI image generator within weeks, creating more natural-looking images and diagrams to compete w...
Evercore ISI Flags Arista Networks (ANET) and IBM (IBM) Stock as Q1 Earnings Win...
Evercore ISI upgrades Arista Networks (ANET) and IBM (IBM) to tactical outperform, expecting both to beat Q1 estimates and raise f...
Amazon (AMZN) Stock: Anthropic’s Explosive Growth Could Fuel AWS Ahead of Earnin...
Amazon (AMZN) stock gets $325 price target from KeyBanc as Anthropic's $30B revenue run rate boosts AWS growth ahead of April 29 e...
Adobe (ADBE) Stock Gains 1.8% Following CX Enterprise AI Agent Platform Launch
Adobe (ADBE) stock climbed 1.8% Monday following the launch of CX Enterprise, an AI agent platform for businesses, despite being d...
Clearmind Medicine (CMND) Stock Doubles as CMND-100 Passes Critical Safety Miles...
Clearmind Medicine (CMND) stock doubled after CMND-100 achieved its primary safety endpoint in a Phase I/IIa AUD trial with no ser...
Enveric Biosciences (ENVB) Stock Explodes 160%+ Following Trump’s Psychedelic Ex...
Enveric Biosciences (ENVB) stock exploded 160%+ after Trump's executive order to accelerate psychedelic drug reviews and $50M ibog...
COMPASS Pathways (CMPS) Stock Soars 25% on Trump’s Psychedelics Research Order
COMPASS Pathways (CMPS) stock jumped 25% after Trump's executive order on psychedelic research. Positive Phase 3 data boosts inves...